杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/04/12 | 1,830 | 1,831 | 1,818 | 1,826 | +4 | +0.2% | 33,300 |
| 2024/04/11 | 1,820 | 1,828 | 1,811 | 1,822 | -11 | -0.6% | 39,700 |
| 2024/04/10 | 1,820 | 1,833 | 1,820 | 1,833 | +11 | +0.6% | 41,800 |
| 2024/04/09 | 1,820 | 1,826 | 1,803 | 1,822 | +2 | +0.1% | 40,300 |
| 2024/04/08 | 1,815 | 1,825 | 1,800 | 1,820 | +11 | +0.6% | 48,500 |
| 2024/04/05 | 1,795 | 1,810 | 1,787 | 1,809 | +14 | +0.8% | 32,700 |
| 2024/04/04 | 1,803 | 1,807 | 1,789 | 1,795 | -10 | -0.6% | 57,000 |
| 2024/04/03 | 1,785 | 1,809 | 1,783 | 1,805 | +14 | +0.8% | 55,000 |
| 2024/04/02 | 1,791 | 1,803 | 1,779 | 1,791 | -13 | -0.7% | 79,000 |
| 2024/04/01 | 1,802 | 1,815 | 1,793 | 1,804 | -8 | -0.4% | 52,600 |
| 2024/03/29 | 1,815 | 1,832 | 1,806 | 1,812 | -5 | -0.3% | 56,400 |
| 2024/03/28 | 1,808 | 1,836 | 1,808 | 1,817 | -40 | -2.2% | 82,500 |
| 2024/03/27 | 1,853 | 1,880 | 1,851 | 1,857 | +21 | +1.1% | 173,600 |
| 2024/03/26 | 1,825 | 1,839 | 1,809 | 1,836 | +2 | +0.1% | 86,900 |
| 2024/03/25 | 1,825 | 1,855 | 1,820 | 1,834 | +19 | +1% | 165,200 |
| 2024/03/22 | 1,800 | 1,823 | 1,796 | 1,815 | +19 | +1.1% | 97,300 |
| 2024/03/21 | 1,800 | 1,812 | 1,795 | 1,796 | +4 | +0.2% | 93,300 |
| 2024/03/19 | 1,785 | 1,792 | 1,779 | 1,792 | +8 | +0.4% | 43,000 |
| 2024/03/18 | 1,799 | 1,799 | 1,780 | 1,784 | -2 | -0.1% | 43,300 |
| 2024/03/15 | 1,784 | 1,797 | 1,776 | 1,786 | +2 | +0.1% | 81,300 |
| 2024/03/14 | 1,785 | 1,785 | 1,768 | 1,784 | +8 | +0.5% | 37,800 |
| 2024/03/13 | 1,785 | 1,793 | 1,768 | 1,776 | -9 | -0.5% | 49,200 |
| 2024/03/12 | 1,788 | 1,788 | 1,761 | 1,785 | -3 | -0.2% | 49,000 |
| 2024/03/11 | 1,803 | 1,803 | 1,776 | 1,788 | -15 | -0.8% | 51,800 |
| 2024/03/08 | 1,781 | 1,811 | 1,781 | 1,803 | +17 | +1% | 129,200 |
| 2024/03/07 | 1,770 | 1,786 | 1,766 | 1,786 | +24 | +1.4% | 65,000 |
| 2024/03/06 | 1,763 | 1,780 | 1,762 | 1,762 | -1 | -0.1% | 59,700 |
| 2024/03/05 | 1,771 | 1,774 | 1,746 | 1,763 | -13 | -0.7% | 44,500 |
| 2024/03/04 | 1,788 | 1,793 | 1,772 | 1,776 | -12 | -0.7% | 51,100 |
| 2024/03/01 | 1,793 | 1,795 | 1,774 | 1,788 | +7 | +0.4% | 59,200 |
| 2024/02/29 | 1,781 | 1,784 | 1,771 | 1,781 | -6 | -0.3% | 87,600 |
| 2024/02/28 | 1,795 | 1,809 | 1,782 | 1,787 | -8 | -0.4% | 62,900 |
| 2024/02/27 | 1,794 | 1,811 | 1,790 | 1,795 | +3 | +0.2% | 85,400 |
| 2024/02/26 | 1,790 | 1,803 | 1,786 | 1,792 | +10 | +0.6% | 84,700 |
| 2024/02/22 | 1,776 | 1,785 | 1,771 | 1,782 | +17 | +1% | 87,900 |
| 2024/02/21 | 1,780 | 1,787 | 1,759 | 1,765 | -19 | -1.1% | 69,700 |
| 2024/02/20 | 1,781 | 1,798 | 1,780 | 1,784 | +12 | +0.7% | 83,600 |
| 2024/02/19 | 1,748 | 1,775 | 1,741 | 1,772 | +36 | +2.1% | 71,500 |
| 2024/02/16 | 1,730 | 1,748 | 1,724 | 1,736 | +24 | +1.4% | 77,900 |
| 2024/02/15 | 1,750 | 1,751 | 1,712 | 1,712 | -28 | -1.6% | 82,000 |
| 2024/02/14 | 1,782 | 1,783 | 1,734 | 1,740 | -40 | -2.2% | 103,700 |
| 2024/02/13 | 1,760 | 1,784 | 1,757 | 1,780 | +20 | +1.1% | 88,900 |
| 2024/02/09 | 1,750 | 1,770 | 1,748 | 1,760 | +2 | +0.1% | 119,200 |
| 2024/02/08 | 1,764 | 1,772 | 1,754 | 1,758 | -6 | -0.3% | 85,600 |
| 2024/02/07 | 1,760 | 1,776 | 1,757 | 1,764 | -12 | -0.7% | 114,100 |
| 2024/02/06 | 1,792 | 1,798 | 1,770 | 1,776 | -4 | -0.2% | 66,600 |
| 2024/02/05 | 1,793 | 1,793 | 1,773 | 1,780 | +6 | +0.3% | 77,500 |
| 2024/02/02 | 1,780 | 1,785 | 1,767 | 1,774 | -3 | -0.2% | 55,500 |
| 2024/02/01 | 1,773 | 1,779 | 1,761 | 1,777 | -7 | -0.4% | 65,700 |
| 2024/01/31 | 1,771 | 1,784 | 1,756 | 1,784 | +7 | +0.4% | 74,700 |
151～
200
件表示中 / 3585件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 149,100円 | +3.2% | +4.5% | 3.49% | 17.13倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ゼリア新薬 | 222,100円 | +13.6% | +29.2% | 2.07% | 11.52倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| ネクセラファーマ | 113,700円 | +197.7% | - | 0.00% | 46.47倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ＪＣＲファーマ | 69,600円 | -3.7% | -36.7% | 2.87% | 22.92倍 | 1.50倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| 栄研化 | 210,100円 | +0.4% | -8.4% | 2.52% | 27.77倍 | 1.58倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
